2021-08-08

Department of General Medicine, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing, China.; Department of General Medicine, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing, China.; Department of Infectious Diseases, The First People's Hospital of Foshan, Foshan, China.; Department of General Medicine, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing, China.

OBJECTIVE: To comprehensively analyze that how liver injury in patients with metabolic syndrome is affected by coronavirus disease 2019 (COVID-19) and provide clinical reference to their prevention and treatment. BACKGROUND: The current COVID-19 pandemic poses a major threat to human life and health. Metabolic syndrome is also a major global health problem, and evidence suggests that patients with metabolic syndrome are at an increased risk of COVID-19 complications. Liver injury is one of the main manifestations of extra-pulmonary organ injury in patients with COVID-19. Currently, the effects of metabolic syndrome on liver injury in patients with COVID-19 are unclear. METHODS: In this study, we searched the PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases for articles on the latest developments of liver injury in COVID-19 patients with metabolic syndrome from 2019 to comprehensively analyze the current knowledge of how liver injury in patients with

2021-03-09

Intensive Care Unit, The Fifth People's Hospital of Suzhou, 10 Guangqian Road, Suzhou, 215000, China.; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215000, China.; Intensive Care Unit, The Fifth People's Hospital of Suzhou, 10 Guangqian Road, Suzhou, 215000, China.; Intensive Care Unit, The Fifth People's Hospital of Suzhou, 10 Guangqian Road, Suzhou, 215000, China.; Intensive Care Unit, The Fifth People's Hospital of Suzhou, 10 Guangqian Road, Suzhou, 215000, China.; Intensive Care Unit, The Fifth People's Hospital of Suzhou, 10 Guangqian Road, Suzhou, 215000, China.; Intensive Care Unit, The Fifth People's Hospital of Suzhou, 10 Guangqian Road, Suzhou, 215000, China.; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215000, China. Electronic address: huang_jian_an@163.com.; Intensive Care Unit, The Fifth People's Hospital of Suzhou, 10 Guangqian Road, Suzhou, 215000, China. Electronic address: shenxinghua2010@163.com.; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215000, China. Electronic address: chencheng@suda.edu.cn.

BACKGROUND: The outbreak of COVID-19 has caused ever-increasing attention and public panic all over the world. Until now, data are limited about the risk factors to virus shedding in COVID-19 infected patients. METHODS: In this retrospective study, data were collected from 87 patients hospitalized with COVID-19 infection in Suzhou. Using Cox proportional hazards regression and Kaplan-Meier survival analysis, the risk factors to COVID-19 RNA shedding was to be established according to demographic information, clinical characteristics, epidemiological history, antiviral medicine and corticosteroid administration. RESULTS: The median duration of COVID-19 RNA shedding from admission was 13.11 ± 0.76 days. There was no significant difference in viral shedding duration in terms of gender, age, history of Hubei province stay, characteristics of chest CT on admission, lymphocytopenia and clinical severity. By Cox proportional hazards model, excessive 200 mg cumulative corticosteroid (HR

2021-02-28

C.S. Mott Center for Human Growth and Development, Department of Obstetrics, Gynecology, Wayne State University, Detroit, Michigan, USA.; C.S. Mott Center for Human Growth and Development, Department of Obstetrics, Gynecology, Wayne State University, Detroit, Michigan, USA.; C.S. Mott Center for Human Growth and Development, Department of Obstetrics, Gynecology, Wayne State University, Detroit, Michigan, USA.; C.S. Mott Center for Human Growth and Development, Department of Obstetrics, Gynecology, Wayne State University, Detroit, Michigan, USA.; C.S. Mott Center for Human Growth and Development, Department of Obstetrics, Gynecology, Wayne State University, Detroit, Michigan, USA.; C.S. Mott Center for Human Growth and Development, Department of Obstetrics, Gynecology, Wayne State University, Detroit, Michigan, USA.; Department of Internal Medicine Wayne State University, Detroit, Michigan, USA.; Department of Computer Science, Wayne State University, Detroit, Michigan, USA.; C.S. Mott Center for Human Growth and Development, Department of Obstetrics, Gynecology, Wayne State University, Detroit, Michigan, USA.

The SARS-CoV-2 pandemic has led to hundreds of thousands of deaths and billions of dollars in economic damage. The immune response elicited from this virus is poorly understood. An alarming number of cases have arisen where COVID-19 patients develop complications on top of the symptoms already associated with SARS, such as thrombosis, injuries of vascular system, kidney, and liver, as well as Kawasaki disease. In this review, a bioinformatics approach was used to elucidate the immune response triggered by SARS-CoV-2 infection in primary human lung epithelial and transformed human lung alveolar. Additionally, examined the potential mechanism behind several complications that have been associated with COVID-19 and determined that a specific cytokine storm is leading to excessive neutrophil recruitment. These neutrophils are directly leading to thrombosis, organ damage, and complement activation via neutrophil extracellular trap release.CI - ©2020 Society for Leukocyte Biology.

2021-02-08

Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Department of Pathology, McGill University, Montreal, Quebec, Canada.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Department of Computational Biology, Carnegie Mellon University, Pittsburgh, Pennsylvania.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Department of Medicine, McGill University, Montreal, Quebec, Canada.; Department of Medicine, McMaster University & St. Joseph's Healthcare, Hamilton, Ontario, Canada.; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Department of Pathology, McGill University, Montreal, Quebec, Canada.; Department of Medicine, McGill University, Montreal, Quebec, Canada.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Department of Pathology, McGill University, Montreal, Quebec, Canada.; Department of Medicine, McGill University, Montreal, Quebec, Canada.; Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.

The COVID-19 pandemic is associated with severe pneumonia and acute respiratory distress syndrome leading to death in susceptible individuals. For those who recover, post-COVID-19 complications may include development of pulmonary fibrosis. Factors contributing to disease severity or development of complications are not known. Using computational analysis with experimental data, we report that idiopathic pulmonary fibrosis (IPF)- and chronic obstructive pulmonary disease (COPD)-derived lung fibroblasts express higher levels of angiotensin-converting enzyme 2 (ACE2), the receptor for SARS-CoV-2 entry and part of the renin-angiotensin system that is antifibrotic and anti-inflammatory. In preclinical models, we found that chronic exposure to cigarette smoke, a risk factor for both COPD and IPF and potentially for SARS-CoV-2 infection, significantly increased pulmonary ACE2 protein expression. Further studies are needed to understand the functional implications of ACE2 on lung fibroblasts

2020-03-26

Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China Department of Laboratory, General Hospital of Central Theater Command, 430015; Wuhan, Hubei province People’s Republic of China Department of Laboratory, General Hospital of Central Theater Command, 430015; Wuhan, Hubei province People’s Republic of China MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, CB2 ; 0QH UK Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China 0000 0004 1760 6682grid.410570.7Department of Biochemistry and Molecular Biology,; Third Military Medical University (Army Medical University), 400038 Chongqing, People’s Republic of China

2020-03-26

Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China Department of Laboratory, General Hospital of Central Theater Command, 430015; Wuhan, Hubei province People’s Republic of China Department of Laboratory, General Hospital of Central Theater Command, 430015; Wuhan, Hubei province People’s Republic of China MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, CB2 ; 0QH UK Department of Disease Control and Prevention, General Hospital of Central Theater; Command, 430015 Wuhan, Hubei province People’s Republic of China 0000 0004 1760 6682grid.410570.7Department of Biochemistry and Molecular Biology,; Third Military Medical University (Army Medical University), 400038 Chongqing, People’s Republic of China

2021-01-31

Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; School of Public Health and Management, Hubei University of Medicine, Shiyan, China.; YEBIO Bioengineering Co., Ltd. of Qingdao, Qingdao, China.; Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.; Public Health and Community Medicine, Faculty of Medicine, Minia University, Minia, Egypt.; Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.; Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China.; Global Health Institute, Wuhan University, Wuhan, China.

BACKGROUND: The new coronavirus (COVID-19) rapidly resulted in a pandemic. We report the characteristics of patients with severe or critical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan city, China, and the risk factors related to infection severity and death. METHODS: We extracted the demographic and clinical data of 7283 patients with severe COVID-19 infection from designated Wuhan hospitals as of 25 February 2020. Factors associated with COVID-19 critical illness and mortality were analysed using logistic- and Cox-regression analyses. RESULTS: We studied 6269 patients with severe COVID-19 illness and 1014 critically ill patients. The median (IQR) age was 64 (53-71) years; 51.2% were male, 38.9% were retirees and 7.4% had self-reported histories of chronic disease. Up to the end of the study, 1180 patients (16.2%) recovered and were discharged, 649 (8.9%) died and the remainder were still receiving treatment. The number of daily confirmed critical

2021-05-30

National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China. hjbian@fmmu.edu.cn.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; College of Military Preventive Medicine, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; Department of Pharmaceutics, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; Department of Pathology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.; College of Military Preventive Medicine, Fourth Military Medical University, Xi'an, China.; Jiangsu Pacific Meinuoke Biopharmaceutical Co. Ltd, Changzhou, China.; Jiangsu Pacific Meinuoke Biopharmaceutical Co. Ltd, Changzhou, China.; Jiangsu Pacific Meinuoke Biopharmaceutical Co. Ltd, Changzhou, China.; Department of Foreign Languages, Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, China. znchen@fmmu.edu.cn.; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. zhuping@fmmu.edu.cn.

Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Blocking CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 replication. Meplazumab is a humanized anti-CD147 IgG(2) monoclonal antibody, which may effectively prevent SARS-CoV-2 infection in coronavirus disease 2019 (COVID-19) patients. Here, we conducted a randomized, double-blinded, placebo-controlled phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of meplazumab in healthy subjects, and an open-labeled, concurrent controlled add-on exploratory phase 2 study to determine the efficacy in COVID-19 patients. In phase 1 study, 59 subjects were enrolled and assigned to eight cohorts, and no serious treatment-emergent adverse event (TEAE) or TEAE grade ≥3 was observed. The serum and peripheral blood C(max) and area under the curve showed non-linear pharmacokinetic characteristics. No obvious relation between